A citation-based method for searching scientific literature

April Armstrong, Kyle Fahrbach, Craig Leonardi, Matthias Augustin, Binod Neupane, Paulina Kazmierska, Marissa Betts, Andreas Freitag, Sandeep Kiri, Vanessa Taieb, Mahmoud Slim, Natalie Nunez Gomez, Richard B Warren. Dermatol Ther (Heidelb) 2022
Times Cited: 2







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, Yukari Okubo, Michael M Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce Strober. Br J Dermatol 2022
3
100

Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig. Dermatol Ther (Heidelb) 2022
6
100


Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
Kyle Fahrbach, Grammati Sarri, David M Phillippo, Binod Neupane, Samantha E Martel, Sandeep Kiri, Kristian Reich. Dermatol Ther (Heidelb) 2021
5
50

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi,[...]. Lancet 2021
53
50

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Andrew Blauvelt, Craig L Leonardi, Melinda Gooderham, Kim A Papp, Sandra Philipp, Jashin J Wu, Atsuyuki Igarashi, Mary Flack, Ziqian Geng, Tianshuang Wu,[...]. JAMA Dermatol 2020
64
50

Blockade of IL-23: What is in the Pipeline?
Tommaso Lorenzo Parigi, Marietta Iacucci, Subrata Ghosh. J Crohns Colitis 2022
2
50



Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease.
Irina Deeva, Serena Mariani, Chiara De Luca, Valeria Pacifico, Luca Leoni, Desanka Raskovic, Zaira Kharaeva, Liudmila Korkina, Saveria Pastore. Cytokine 2010
39
50

Psoriatic erythroderma: a histopathologic study of forty-five patients.
C Tomasini, F Aloi, C Solaroli, M Pippione. Dermatology 1997
14
50

Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis.
G Avallone, C Cariti, P Dapavo, M Ortoncelli, L Conforto, L Mastorino, G Roccuzzo, F Cavallo, M Rubatto, P Quaglino,[...]. J Eur Acad Dermatol Venereol 2022
5
50

Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Leonardo Pescitelli, Valentina Dini, Paolo Gisondi, Francesco Loconsole, Stefano Piaserico, Angelo Piccirillo, Giuseppe Stinco, Enzo Errichetti, Marina Talamonti, Lara Tripo,[...]. J Dermatol Sci 2015
11
50


Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Philip Mease, Christina Charles-Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Huifeng Yun, Joel Kremer, Jeffrey Greenberg, Wendi Malley, Alina Onofrei,[...]. Ann Rheum Dis 2020
78
50

Treatment of erythrodermic psoriasis with etanercept.
M Esposito, A Mazzotta, C de Felice, M Papoutsaki, S Chimenti. Br J Dermatol 2006
36
50


Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study.
Giovanni Damiani, Alessia Pacifico, Filomena Russo, Paolo Daniele Maria Pigatto, Nicola Luigi Bragazzi, Claudio Bonifati, Aldo Morrone, Abdulla Watad, Mohammad Adawi. J Clin Med 2019
14
50

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
81
50




Serum immunoglobulins in psoriatic erythroderma.
L-F Li, S A Sujan, H Yang, W-H Wang. Clin Exp Dermatol 2005
23
50

Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
Sunil Dogra, Anuradha Bishnoi, Tarun Narang, Sanjeev Handa. Dermatol Ther 2018
9
50


Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Xanthippe-Argyro Koutsoukou, Evangelia Papadavid, Konstantinos Theodoropoulos, Dimitris Rigopoulos. Dermatol Ther 2014
8
50

Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
J Santos-Juanes, P Coto-Segura, A Mas-Vidal, C Galache Osuna. Br J Dermatol 2010
29
50

Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Ahmed A Suleiman, Amit Khatri, Rajneet K Oberoi, Ahmed A Othman. Clin Pharmacokinet 2020
10
50

Total Serum Immunoglobulin E Levels in Patients with Psoriasis.
Emina Kasumagic-Halilovic. Mater Sociomed 2020
8
50

Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.
Aya Nishizawa, Takahiro Satoh, Hiroo Yokozeki. Acta Derm Venereol 2012
7
50

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Richard G Langley, April Armstrong, Richard B Warren, Kenneth B Gordon, Joseph F Merola, Yukari Okubo, Cynthia Madden,[...]. Lancet 2021
55
50

Analysis of Th1/Th2 response pattern for erythrodermic psoriasis.
Ping Zhang, Hong-Xiang Chen, Yi-Qun Duan, Wei-Zhen Wang, Tian-Zhu Zhang, Jia-Wen Li, Ya-Ting Tu. J Huazhong Univ Sci Technolog Med Sci 2014
20
50

Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.
Misha Rosenbach, Sylvia Hsu, Neil J Korman, Mark G Lebwohl, Melodie Young, Bruce F Bebo, Abby S Van Voorhees. J Am Acad Dermatol 2010
87
50

Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Hannele Heikkilä, Annamari Ranki, Suvi Cajanus, Seija-Liisa Karvonen. Arch Dermatol 2005
25
50

Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
Laura Pizzatti, Cristina Mugheddu, Silvia Sanna, Laura Atzori, Franco Rongioletti. Dermatol Ther 2020
3
50

Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment.
U F Haustein, M Rytter. J Eur Acad Dermatol Venereol 2000
92
50

Treating psoriasis in the elderly: biologics and small molecules.
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Elisa Camela. Expert Opin Biol Ther 2022
6
50

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
Andrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, April W Armstrong, Baojin Zhu, Russel Burge, Gaia Gallo, Jiaying Guo, Alyssa Garrelts, Mark Lebwohl. Dermatol Ther (Heidelb) 2022
1
100

Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis.
Huixia Wang, Sijia Wang, Liang Li, Xiuying Wang, Chengfei Liu, Mei Lu, Yumin Xia, Yale Liu. Cytokine 2021
8
50


TWEAK/Fn14 Is Overexpressed in Crohn's Disease and Mediates Experimental Ileitis by Regulating Critical Innate and Adaptive Immune Pathways.
Luca Di Martino, Abdullah Osme, Sarah Kossak-Gupta, Theresa T Pizarro, Fabio Cominelli. Cell Mol Gastroenterol Hepatol 2019
5
50

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, Alexander Egeberg, Jashin J Wu. Am J Clin Dermatol 2021
21
50


Two cases of Erythrodermic psoriasis treated with Golimumab.
Mayssoun Kudsi, Mhd Amin Alzabibi, Mosa Shibani. Ann Med Surg (Lond) 2022
1
100

Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
Else N Kop, John E M Körver, Delphine Van Ruysevelt, Elke M G J De Jong, Pieter G Van der Valk, Peter C M Van de Kerkhof. J Dermatolog Treat 2009
5
50

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases.
Ye Seul Kim, Hyun Ju Kim, Sanghoon Lee, Young Lip Park. Ann Dermatol 2016
5
50

Psoriasiform exfoliative erythroderma induced by golimumab.
S Mateo, F J García-Martínez, D Sánchez-Aguilar, J Amarelo, J Toribio. Clin Exp Dermatol 2014
4
50

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
Akimichi Morita, Yukari Okubo, Yoji Morisaki, Hitoe Torisu-Itakura, Yoshinori Umezawa. Dermatol Ther (Heidelb) 2022
6
50

IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation.
Luisa Senra, Alessio Mylonas, Ruairi D Kavanagh, Padraic G Fallon, Curdin Conrad, Julia Borowczyk-Michalowska, Ludovic Jean Wrobel, Guerkan Kaya, Nikhil Yawalkar, Wolf-Henning Boehncke,[...]. J Invest Dermatol 2019
27
50

Psoriasis.
Frank O Nestle, Daniel H Kaplan, Jonathan Barker. N Engl J Med 2009
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.